Novartis is a large pharma headquartered in Switzerland. Over the past three years, Novartis has been involved in 57 licensing and acquisition transactions, with a primary focus on Gene Therapy (14 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
27
Active Trials
50
Top Modality
Gene Therapy
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Novartis in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| AAV9 and AAV vector technologies | Nationwide Children's Hospital and REGENXBIO | Gene Therapy | Unknown | license | Apr 2026 |
| AAV9-based SMA gene replacement therapies | Nationwide Children's Hospital, REGENXBIO, and Généthon | Gene Therapy | Approved | license | Apr 2026 |
| AAV9 CNS delivery for SMA | Généthon | Gene Therapy | Discovery | license | Apr 2026 |
| AAV vectors for SMA | REGENXBIO | Gene Therapy | Discovery | license | Apr 2026 |
| AAV9 delivery for SMA | Nationwide Children's Hospital | Gene Therapy | Discovery | license | Apr 2026 |
| MOR106 | Galapagos | Antibodies | Unknown | license | Mar 2026 |
| PIK3CA breast cancer drug | Synnovation Therapeutics | Small Molecules | Unknown | acquisition | Mar 2026 |
| SNV4818 | Synnovation Therapeutics | Small Molecules | Phase 1 | acquisition | Mar 2026 |
| SNV-4818 | Novartis AG | Small Molecules | Phase 1 | license | Mar 2026 |
| SNV4818 | Pikavation Therapeutics | Small Molecules | Phase 1 | acquisition | Mar 2026 |
Showing 10 of 20 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Novartis is most active based on deal history and clinical trial data.
Key indicators of Novartis's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Novartis has 50 active clinical trials across 6 development phases.
2
Not Applicable
3
Phase 4
18
Unknown
11
Phase 1
12
Phase 2
4
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Novartis is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 57 deals over the past three years, Novartis ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Novartis include Oncology (24 deals and trials), Rare Disease (15 deals and trials), Cardiovascular (15 deals and trials), and Neurology (10 deals and trials). In terms of modality, Novartis has shown particular interest in gene therapy, antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Novartis and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Novartis's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals